We included randomized control trials (RCTs) in which PDE5 inhibitors were compared to a placebo or any other treatment in adults with pulmonary hypertension from any cause, irrespective of the World Health Organization (WHO) functional class and group of pulmonary hypertension. This evidence concerns the gene PDE5A and pulmonary hypertension.